-
Curtis and colleagues from the University of Alabama at Birmingham measured the rate of hip fracture among women who discontinued bisphosphonate therapy compared with women who remained on treatment.
-
The Women's Iinternational Study of Long Duration Oestrogen after the Menopause (WISDOM) trial was a randomized, controlled trial in the United Kingdom, Australia, and New Zealand, of 3721 women aged 50-69 treated with either combined 0.625 mg conjugated estrogens and 2.5/5.0 mg medroxyprogesterone, or placebo. The original plan was to randomize 22,300 women to the study that would last 10 years.
-
One of the most common and poignant questions an ovarian cancer patient asks upon learning of her diagnosis is, "How did I get this?
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
The stars were aligned when four papers appeared in two obstetrical journals within a month of each other dealing with the optimal time in gestation to deliver.
-
The above study involved a detailed analysis of data obtained in the observational arm of the Women's Health Initiative. As a rationale, the authors note that obesity is a well-established risk factor for breast cancer.
-
Cromer et al performed a 24-month observational, prospective cohort study of adolescents in the Midwest using depot medroxyprogesterone acetate (DMPA), oral contraceptives (OCs), or nothing. DEXA scans were performed at baseline and 6-month intervals.
-
A 3-year randomized, double-blind clinical trial in 206 sites throughout the world compared bazedoxifene (20 mg or 40 mg) and raloxifene (60 mg) with placebo.
-
A randomized, double-blind, placebo-controlled trial comparing Ginkgo biloba with placebo for the prevention of dementia enrolled 3069 elderly individuals (older than age 75) in 5 academic centers in the United States.
-
In this issue: Drug combinations for hypertension; tenecteplase for out-of-hospital cardiac arrest; CAM most commonly used for back, neck, and arthritis pain; FDA Actions.
